Cleo Diagnostics (ASX:COV) Total Payout Yield % : 0.00 (As of May. 23, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Cleo Diagnostics's current Total Payout Yield % is 0.00%.

Cleo Diagnostics Total Payout Yield % Historical Data

The historical data trend for Cleo Diagnostics's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Total Payout Yield % Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Total Payout Yield %

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Total Payout Yield %	-	-	-103.76

Competitive Comparison of Cleo Diagnostics's Total Payout Yield %

For the Medical Devices subindustry, Cleo Diagnostics's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics's Total Payout Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Total Payout Yield % falls into.

Cleo Diagnostics Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Cleo Diagnostics's Total Payout Yield % for the fiscal year that ended in Jun. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	0	+	0)	/	0
	=	N/A%

Cleo Diagnostics's annualized Total Payout Yield % for the quarter that ended in Dec. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (0	+	12	+	0)	*	2	/	23.13
	=	-103.76%

Cleo Diagnostics Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

Cleo Diagnostics Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines